NASDAQ: NDRA) Targets Billions With TAEUS® Liver Imaging Technology" src="https://www.abnewswire.com/upload/2026/04/1776092379.jpg" alt="ENDRA Life Sciences (NASDAQ: NDRA) Targets Billions With TAEUS® Liver Imaging Technology" width="225" height="225">

As the global race to treat metabolic dysfunction–associated steatotic liver disease (MASLD) and expand GLP-1 therapies accelerates, a critical challenge is emerging across the pharmaceutical industry: clinical trial infrastructure is struggling to scale—especially liver imaging.

With trial sizes increasing, durations extending, and global participation expanding, ENDRA Life Sciences (NASDAQ: NDRA) is positioning its TAEUS® (Thermo-Acoustic Enhanced UltraSound) technology as a potential solution to one of the largest inefficiencies in modern clinical trials.

Alongside ENDRA Life Sciences (NASDAQ: NDRA), other names drawing attention include Allogene Therapeutics (NASDAQ: ALLO), Nokia Corporation (NASDAQ: NOK), ImageneBio Inc (NASDAQ: IMA), and Sky Quarry Inc (NASDAQ: SKYQ), currently trading actively in early trading.

GLP-1 and MASLD Market Growth Is Outpacing Diagnostic Infrastructure

The GLP-1 receptor agonist market, a key driver of metabolic disease treatment, is projected to grow from approximately $66.4 billion in 2025 to over $185 billion by 2033. At the same time:

• Up to 30 million Americans are expected to be on GLP-1 therapies by 2030
• MASLD and MASH clinical programs are expanding globally
• Trials increasingly require longitudinal liver fat monitoring over 48–72 weeks

These dynamics are creating unprecedented demand for scalable liver imaging solutions.

MRI-Based Imaging Creates a Structural Bottleneck

Currently, MRI-PDFF remains the gold standard for liver fat measurement in clinical trials. However, it introduces significant constraints:

• Cost per scan: $1,500–$3,000
• Limited availability across global trial sites
• Dependence on hospital-based infrastructure
• Scheduling and throughput limitations

As trials scale into thousands of patients across hundreds of sites, imaging becomes a major cost driver and execution bottleneck.

TAEUS®: A Potential Reset of Clinical Trial Economics

ENDRA’s TAEUS® platform is designed to address these limitations by leveraging:

• Ultrasound-based infrastructure
• Point-of-care deployment
• Rapid, repeatable liver fat measurement

Internal modeling suggests that replacing MRI-based workflows with TAEUS could reduce imaging costs by approximately 90% to 96% per trial.

This represents more than incremental savings—it signals a potential structural reset in how clinical trial imaging is performed and funded.

Multi-Billion Dollar Efficiency Opportunity

At scale, the impact becomes significant.

ENDRA estimates that widespread adoption of TAEUS across GLP-1 and MASLD clinical trials could result in:

• Approximately $3.1 billion in imaging-related savings by 2025
• Expanding to roughly $7.0 billion by 2029

These projections reflect growing trial sizes, repeated imaging requirements, and broader global deployment.

The Bottom Line

The expansion of MASLD and GLP-1 therapies is creating parallel demand for scalable diagnostic infrastructure.

As clinical trials grow in size and complexity, imaging constraints are becoming increasingly visible.

ENDRA Life Sciences (NASDAQ: NDRA) is developing TAEUS to address this gap—offering a potential pathway to:

• Reduce imaging costs by over 90%
• Unlock billions in system-wide efficiencies
• Enable the next phase of global metabolic disease treatment

In a healthcare market defined by scale, infrastructure—not just innovation—may determine who wins.

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com